RU2018112257A - Оптимизация растворимости иммуносвязывающих средств - Google Patents
Оптимизация растворимости иммуносвязывающих средств Download PDFInfo
- Publication number
- RU2018112257A RU2018112257A RU2018112257A RU2018112257A RU2018112257A RU 2018112257 A RU2018112257 A RU 2018112257A RU 2018112257 A RU2018112257 A RU 2018112257A RU 2018112257 A RU2018112257 A RU 2018112257A RU 2018112257 A RU2018112257 A RU 2018112257A
- Authority
- RU
- Russia
- Prior art keywords
- amino acid
- heavy chain
- acid position
- immunobinding agent
- serine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Claims (14)
1. Иммуносвязывающее средство, содержащее следующие повышающие растворимость мотивы в аминокислотных положениях 12, 103 и 144 тяжелой цепи (Система нумерации AHo):
(a) серин (S) в аминокислотном положении 12 тяжелой цепи;
(b) серин (S) в аминокислотном положении 103 тяжелой цепи; и
(c) серин (S) в аминокислотном положении 144 тяжелой цепи;
где иммуносвязывающее средство содержит вариабельную область тяжелой цепи или ее фрагмент.
2. Иммуносвязывающее средство по п. 1, дополнительно содержащее
(a) аспарагиновую кислоту (D) в аминокислотном положении 31 легкой цепи;
(b) глютаминовую кислоту (E) в аминокислотном положении 83 легкой цепи;
(c) аргинин (R) в аминокислотном положении 43 тяжелой цепи;
(d) лейцин (L) в аминокислотном положении 67 тяжелой цепи; и/или
(e) аланин (A) в аминокислотном положении 78 тяжелой цепи.
3. Иммуносвязывающее средство по п. 1 или 2, которое представляет собой scFv антитело, полноразмерный иммуноглобулин, Fab фрагмент, Dab или вариабельную область тяжелой цепи, содержащую единственный вариабельный домен или два константных домена.
4. Иммуносвязывающее средство по п. 3, где иммуносвязывающее средство специфически связывается с TNFα человека или VEGF человека.
5. Композиция, содержащая, иммуносвязывающее средство по п. 1 и фармацевтически приемлемый носитель.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7569208P | 2008-06-25 | 2008-06-25 | |
| US61/075,692 | 2008-06-25 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014104577A Division RU2653441C2 (ru) | 2008-06-25 | 2014-02-10 | Оптимизация растворимости иммуносвязывающих средств |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2018112257A true RU2018112257A (ru) | 2019-10-09 |
Family
ID=41228195
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011102548/10A RU2514658C2 (ru) | 2008-06-25 | 2009-06-25 | Оптимизация растворимости иммуносвязывающих средств |
| RU2014104577A RU2653441C2 (ru) | 2008-06-25 | 2014-02-10 | Оптимизация растворимости иммуносвязывающих средств |
| RU2018112257A RU2018112257A (ru) | 2008-06-25 | 2018-04-05 | Оптимизация растворимости иммуносвязывающих средств |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011102548/10A RU2514658C2 (ru) | 2008-06-25 | 2009-06-25 | Оптимизация растворимости иммуносвязывающих средств |
| RU2014104577A RU2653441C2 (ru) | 2008-06-25 | 2014-02-10 | Оптимизация растворимости иммуносвязывающих средств |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US9556265B2 (ru) |
| EP (2) | EP3241843B1 (ru) |
| JP (3) | JP5745720B2 (ru) |
| KR (2) | KR101650165B1 (ru) |
| CN (2) | CN102076715B (ru) |
| AU (1) | AU2009264566B2 (ru) |
| BR (1) | BRPI0914666A2 (ru) |
| CA (1) | CA2728829C (ru) |
| CY (2) | CY1119626T1 (ru) |
| DK (2) | DK2307455T3 (ru) |
| ES (2) | ES2884117T3 (ru) |
| HR (2) | HRP20171250T1 (ru) |
| HU (2) | HUE034827T2 (ru) |
| LT (2) | LT3241843T (ru) |
| MX (2) | MX346024B (ru) |
| PL (2) | PL2307455T3 (ru) |
| PT (2) | PT3241843T (ru) |
| RU (3) | RU2514658C2 (ru) |
| SI (2) | SI2307455T1 (ru) |
| WO (1) | WO2009155725A1 (ru) |
| ZA (1) | ZA201008595B (ru) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8349322B2 (en) | 2008-06-25 | 2013-01-08 | ESBATech, an Alcon Biomedical Research Unit, LLC | Stable and soluble antibodies inhibiting VEGF |
| CA2728829C (en) | 2008-06-25 | 2018-01-02 | Esbatech, An Alcon Biomedical Research Unit Llc | Solubility optimization of immunobinders |
| ES2687259T5 (es) | 2008-06-25 | 2022-10-14 | Novartis Ag | Anticuerpos estables y solubles que inhiben TNF |
| CN102164958A (zh) | 2008-06-25 | 2011-08-24 | 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 | 使用通用抗体构架进行的兔抗体的人源化 |
| US8399624B1 (en) | 2009-06-25 | 2013-03-19 | Esbatech, An Alcon Biomedical Research Unit Llc | Acceptor framework for CDR grafting |
| CA2777527C (en) * | 2009-12-23 | 2020-06-23 | Esbatech, An Alcon Biomedical Research Unit Llc | Method for decreasing immunogenicity |
| AU2014262201B2 (en) * | 2009-12-23 | 2016-09-15 | Novartis Ag | Method for decreasing immunogenicity |
| UY33679A (es) | 2010-10-22 | 2012-03-30 | Esbatech | Anticuerpos estables y solubles |
| US20130310281A1 (en) * | 2011-02-02 | 2013-11-21 | Glaxo Group Limited | Novel antigen binding proteins |
| KR102345999B1 (ko) | 2012-11-05 | 2021-12-30 | 델레넥스 쎄라퓨틱스 아게 | Il-1 베타 결합성분 |
| EP2931750B8 (en) | 2012-12-17 | 2021-11-03 | Cell Medica Inc. | Antibodies against il-1 beta |
| RU2015139095A (ru) * | 2013-02-15 | 2017-03-21 | ИЭсБиЭйТЕК - Э НОВАРТИС КОМПАНИ ЭлЭлСи | Акцепторный каркасный участок для пересадки cdr |
| RU2015139890A (ru) * | 2013-02-20 | 2017-03-27 | ИЭсБиЭйТЕК - Э НОВАРТИС КОМПАНИ ЭлЭлСи | Акцепторный каркасный участок для пересадки cdr |
| SG11201601044XA (en) | 2013-08-12 | 2016-03-30 | Genentech Inc | Compositions and method for treating complement-associated conditions |
| JP6580570B2 (ja) * | 2013-09-06 | 2019-09-25 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗体安定性を向上させるための方法 |
| MA39934A (fr) | 2014-05-01 | 2017-03-08 | Hoffmann La Roche | Variants d'anticorps anti-facteur d et leurs utilisations |
| ES2685917T3 (es) * | 2015-10-21 | 2018-10-15 | Trinseo Europe Gmbh | Dienos funcionalizados con aminosilano para el uso en la funcionalización de polímeros elastoméricos |
| CN116082505A (zh) | 2016-02-25 | 2023-05-09 | 细胞医学公司 | Pd-l1的结合成员 |
| AU2022219517A1 (en) | 2021-02-12 | 2023-07-13 | Boehringer Ingelheim International Gmbh | Complement c3 antigen binding proteins |
| WO2022190007A1 (en) | 2021-03-09 | 2022-09-15 | Cdr-Life Ag | Rabbit-derived antigen binding protein nucleic acid libraries |
| KR20230169944A (ko) | 2021-03-09 | 2023-12-18 | 씨디알-라이프 아게 | Mage-a4 펩티드-mhc 항원 결합 단백질 |
| WO2023110918A1 (en) | 2021-12-14 | 2023-06-22 | Cdr-Life Ag | Dual mhc-targeting t cell engager |
| US20240091262A1 (en) | 2022-09-14 | 2024-03-21 | Cdr-Life Ag | Mage-a4 peptide dual t cell engagers |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824307A (en) | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| DK0669836T3 (da) | 1992-11-13 | 1996-10-14 | Idec Pharma Corp | Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom |
| US6740734B1 (en) | 1994-01-14 | 2004-05-25 | Biovitrum Ab | Bacterial receptor structures |
| HU230048B1 (hu) | 1996-02-09 | 2015-06-29 | Abbvie Biotechnology Ltd | Humán TNFalfa-kötő antitestek alkalmazása |
| ATE253593T1 (de) | 1996-07-16 | 2003-11-15 | Plueckthun Andreas Prof Dr | Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| ES2301198T3 (es) | 1997-06-12 | 2008-06-16 | Novartis International Pharmaceutical Ltd. | Polipeptidos artificiales de anticuerpos. |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| EP1946775A3 (en) | 1998-08-11 | 2008-08-06 | Biogen Idec Inc. | Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| SE9901379D0 (sv) | 1999-04-19 | 1999-04-19 | Pharmacia & Upjohn Ab | Receptor structures |
| US6602977B1 (en) | 1999-04-19 | 2003-08-05 | Biovitrum Ab | Receptor structures |
| EP1242457B1 (en) | 1999-12-28 | 2004-08-11 | Esbatech AG | Intrabodies with defined framework that is stable in a reducing environment and applications thereof |
| MXPA02008178A (es) * | 2000-02-25 | 2004-04-05 | Us Gov Health & Human Serv | Scfvs anti-egfrviii con citotoxicidad y rendimiento mejorados, inmunotoxinas en base a los mismos y metodos para su uso. |
| DE60140474D1 (de) | 2000-09-08 | 2009-12-24 | Univ Zuerich | Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| DK1390535T3 (da) | 2001-04-26 | 2010-12-06 | Amgen Mountain View Inc | Kombinatoriske biblioteker af monomer-domæner |
| US6905608B2 (en) | 2002-01-22 | 2005-06-14 | Exergy Technologies Corporation | Advanced electrodeionization for fluid recycling |
| ES2399617T3 (es) | 2002-05-22 | 2013-04-02 | Esbatech - A Novartis Company Llc | Regiones de marco de inmunoglobulina que demuestran estabilidad potenciada en el entorno intracelulcar y métodos de identificación de las mismas |
| RS20150135A1 (en) * | 2003-05-30 | 2015-08-31 | Genentech Inc. | TREATMENT WITH ANTI-VEGF ANTIBODIES |
| EP1658308A1 (en) | 2003-08-25 | 2006-05-24 | Pieris ProteoLab AG | Muteins of a bilin-binding protein with affinity for a given target |
| EP1773872B1 (en) | 2004-05-21 | 2017-03-15 | The Uab Research Foundation | Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof |
| WO2006131013A2 (en) | 2005-06-07 | 2006-12-14 | Esbatech Ag | STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα |
| JP2009542232A (ja) | 2006-07-10 | 2009-12-03 | エスバテック・アーゲー | 上皮および／または内皮層を通過するｓｃＦｖ抗体 |
| NZ579594A (en) | 2007-03-12 | 2012-03-30 | Esbatech Alcon Biomed Res Unit | Sequence based engineering and optimization of single chain antibodies |
| DK2164961T3 (en) | 2007-06-25 | 2015-03-02 | Esbatech Alcon Biomed Res Unit | Sequence based forward position and optimization of single chain antibodies |
| CA2689941C (en) | 2007-06-25 | 2019-10-29 | Esbatech Ag | Methods of modifying antibodies, and modified antibodies with improved functional properties |
| CA2728829C (en) | 2008-06-25 | 2018-01-02 | Esbatech, An Alcon Biomedical Research Unit Llc | Solubility optimization of immunobinders |
-
2009
- 2009-06-25 CA CA2728829A patent/CA2728829C/en active Active
- 2009-06-25 ES ES17161990T patent/ES2884117T3/es active Active
- 2009-06-25 PT PT171619901T patent/PT3241843T/pt unknown
- 2009-06-25 CN CN200980123815.6A patent/CN102076715B/zh active Active
- 2009-06-25 HU HUE09768694A patent/HUE034827T2/en unknown
- 2009-06-25 MX MX2013011865A patent/MX346024B/es unknown
- 2009-06-25 EP EP17161990.1A patent/EP3241843B1/en active Active
- 2009-06-25 ES ES09768694.3T patent/ES2629345T3/es active Active
- 2009-06-25 DK DK09768694.3T patent/DK2307455T3/en active
- 2009-06-25 KR KR1020117001959A patent/KR101650165B1/ko active IP Right Grant
- 2009-06-25 BR BRPI0914666A patent/BRPI0914666A2/pt not_active Application Discontinuation
- 2009-06-25 SI SI200931674A patent/SI2307455T1/sl unknown
- 2009-06-25 AU AU2009264566A patent/AU2009264566B2/en active Active
- 2009-06-25 MX MX2011000074A patent/MX2011000074A/es active IP Right Grant
- 2009-06-25 US US13/000,460 patent/US9556265B2/en active Active
- 2009-06-25 PL PL09768694T patent/PL2307455T3/pl unknown
- 2009-06-25 HU HUE17161990A patent/HUE056090T2/hu unknown
- 2009-06-25 LT LTEP17161990.1T patent/LT3241843T/lt unknown
- 2009-06-25 SI SI200932137T patent/SI3241843T1/sl unknown
- 2009-06-25 KR KR1020167017202A patent/KR101790567B1/ko active IP Right Grant
- 2009-06-25 LT LTEP09768694.3T patent/LT2307455T/lt unknown
- 2009-06-25 EP EP09768694.3A patent/EP2307455B1/en not_active Revoked
- 2009-06-25 WO PCT/CH2009/000221 patent/WO2009155725A1/en active Application Filing
- 2009-06-25 DK DK17161990.1T patent/DK3241843T3/da active
- 2009-06-25 JP JP2011515050A patent/JP5745720B2/ja active Active
- 2009-06-25 PT PT97686943T patent/PT2307455T/pt unknown
- 2009-06-25 PL PL17161990T patent/PL3241843T3/pl unknown
- 2009-06-25 CN CN201511018105.0A patent/CN105418763A/zh active Pending
- 2009-06-25 RU RU2011102548/10A patent/RU2514658C2/ru active
-
2010
- 2010-11-30 ZA ZA2010/08595A patent/ZA201008595B/en unknown
-
2014
- 2014-02-10 RU RU2014104577A patent/RU2653441C2/ru active
- 2014-03-18 JP JP2014054856A patent/JP2014111667A/ja active Pending
-
2016
- 2016-04-06 JP JP2016076318A patent/JP2016128517A/ja active Pending
- 2016-12-14 US US15/378,649 patent/US10221237B2/en active Active
-
2017
- 2017-06-22 CY CY20171100670T patent/CY1119626T1/el unknown
- 2017-08-16 HR HRP20171250TT patent/HRP20171250T1/hr unknown
-
2018
- 2018-04-05 RU RU2018112257A patent/RU2018112257A/ru not_active Application Discontinuation
-
2019
- 2019-02-05 US US16/267,460 patent/US11046757B2/en active Active
-
2021
- 2021-08-25 HR HRP20211356TT patent/HRP20211356T1/hr unknown
- 2021-09-22 CY CY20211100832T patent/CY1124644T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018112257A (ru) | Оптимизация растворимости иммуносвязывающих средств | |
| RU2013138469A (ru) | АНТИТЕЛА К ИНТЕРЛЕЙКИНУ-1α И СПОСОБЫ ПРИМЕНЕНИЯ | |
| RS54163B1 (en) | ANTI-CD22 ANTIBODIES, THEIR IMMUNCONJUGATES AND THEIR USE | |
| RS53239B (en) | HUMAN ANTI-ANTIBODY ANTIBODIES AND THEIR USES | |
| RU2012130945A (ru) | Способ снижения иммуногенности | |
| HRP20191299T1 (hr) | Formulacije protutijela | |
| RS53258B (en) | HUMAN ANTIBODIES AGAINST HEPATITIS C (HCV) VIRUS AND USE | |
| RS54111B1 (en) | ANTI-ALPHA 2 INTEGRIN ANTIBODIES AND THEIR USES | |
| FR2921928B1 (fr) | Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal | |
| RS52860B (en) | ANTI-ILT7 ANTITELO | |
| RS53157B (en) | SCLEROSTINE ANTIBODIES | |
| PE20130643A1 (es) | Conjugados de anticuerpos multifuncionales | |
| BR112013003262A2 (pt) | anticorpos melhorados da classe igg4. | |
| RS51468B (en) | COMPLETE HUMAN ANTIBODIES FOR HUMANS 4-1BB (CD137) | |
| RU2015103460A (ru) | Ковалентно связанные конъюгаты антиген-антитело | |
| RS54046B1 (en) | ANTI-MIOSTATIN ANTITELA | |
| ES2572177T3 (es) | Anticuerpos neutralizantes anti-B7RP1 humanos | |
| CR8698A (es) | Anticuerpos monoclonales al factor de crecimiento de hepatocito | |
| NZ611859A (en) | Antibody purification | |
| RS54299B1 (en) | COMPOSITIONS AND METHODS OF USING THERAPY ANTIBODIES | |
| RS53760B1 (en) | HUMAN ANTIBODIES RELATING TO MESOTELINE AND THEIR USES | |
| RS53661B1 (en) | HIGH AFINITY ANTIBODY ANTIBODIES TO THE HUMAN NERVOUS FACTOR OF GROWTH | |
| MX2009002711A (es) | Anticuerpos anti-receptor de folato alfa humanos y fragmentos de anticuerpo para la radioinmunoterapia de carcinoma de ovario. | |
| RS53270B (en) | MONOCLONAL ANTIBODIES AGAINST AMYLOID BETA PROTEINS AND THEIR USE | |
| PE20081634A1 (es) | Fab ab pegilado |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20210406 |